GSK, net profit tripled to 17 billion euros, record sales of herpes zoster vaccine – Corriere.it

British pharmaceutical group GlaxoSmithKline (GSK) saw its share of Group net profit more than tripled in 2022, to £15bn (almost 17 billion euros), thanks to the division of the consumer care business. GSK split in July last year from the subsidiary which debuted on the London Stock Exchange under the name of Haleon. The total gain from the split for the full year was £10.1 billion, according to a statement from the drugmaker.

Quarterly accounts

Adjusted earnings of 25.8 pence (about 30 euro cents) per share on sales of about £7.4 billion (€8.3 billion) in the fourth quarter of 2022. Analysts had expected earnings on average adjusted by 21.2 pence (nearly 25 euro cents) per share on revenue of about £7.1 billion (€8 billion), according to a consensus provided by the company. The Shingrix vaccine (for shingles) generated £769 million (more than €870 million) in the quarter, exceeding the £748 million market expectations. 2022 was a pivotal year for GSK – commented the CEO, Emma Walmsley -, which achieved the radical change in performance we are committed to, driven by strong growth in specialty medicines and vaccines, including record sales of Shingrix. We enter 2023 with good momentum, reinforcing confidence in our ambitious sales and profit outlook for 2026.

Forecast 2023

GSK expects 2023 revenue to rise between 6% and 8%, adjusted operating profit expected to increase between 10% and 12% and EPS to increase between 12% and 15%. At the same time, we continue to build a stronger portfolio and pipeline based on infectious disease and immune system science, including our potential new RSV vaccine,” Walmsley added. that GSK will also be in a strong position to deliver growth from 2026 onwards